Translation Of Glaucoma Blindness Genes To Improve Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$856,795.00
Summary
Glaucoma is a common cause of irreversible blindness. It is currently difficult to predict which patients with the earliest signs of glaucoma will develop blinding stages of the disease. This study will investigate how genes and eye measurements can be used to predict the risk of developing severe glaucoma in people with early signs of disease. This will ensure that high risk individuals can access treatment early, while those at low risk can be spared unnecessary treatment and seen less often.
Gene Tests For Predicting Risk Of Developing Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$956,020.00
Summary
Glaucoma is a common cause of blindness. It is currently difficult to predict which patients with the earliest signs of glaucoma will go on to develop the blinding stages of the disease. This study will investigate how genes and othe eye measurements can be used to predict risk of developing glaucoma in people with early signs of disease.
Genome-wide Association Study (GWAS) For Juvenile-onset Myopia And Its Component Measures To Identify Molecular Pathways To Prevent Myopia
Funder
National Health and Medical Research Council
Funding Amount
$495,364.00
Summary
We will examine 2,000 young adults from the Western Australian Raine Cohort at the Lions Eye Institute / University of Western Australia. Ocular data will be collected relating to myopia (short-sightedness) and will be combined with extensive previous childhood and genetic research data collected on the Cohort, to investigate the genetic and environmental factors predisposing to myopia. This will assist in understanding the factors leading to myopia.
A Randomised, Multi-Centre, Placebo Controlled Trial Of Fenofibrate For Treatment Of Diabetic Macular Oedema With Economic Evaluation (FORTE Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,588,132.00
Summary
Our project aims to test if adding an inexpensive oral medication, fenofibrate, is effective at improving treatment of diabetic macular oedema. We will use a well-designed, adequately powered, multi-centred randomised placebo controlled trial to test if fenofibrate can treat currently untreatable forms of diabetic macular oedema, and if it can be combined with current treatments to improve outcomes and reduce costs and risks to patients.